VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatry VLS-01 ...

Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...

n (Participants) = number of study participants with at least one event in the corresponding category n (Events) = number of events in the corresponding category and treatment group N = total number ...

atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant ...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global ...

The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...

The healthcare and life sciences industries have witnessed remarkable advancements in recent years, thanks primarily to the integration of generative artificial intelligence (GenAI) technologies.

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Safety and efficacy results from this study support ...

Stock is on track for its second-biggest one-day gain The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial ...